Boehringer pays $358m upfront for options on six SBP Group cancer drugs worth up to $7bn

Boehringer Ingelheim will pay $358 million upfront for options on up to six cancer drug candidates from China's Sino Biopharma (SBP Group), under a licensing deal disclosed on 4 November 2026¹. A further $7 billion is available in milestone payments, and SBP Group could receive royalties of up to double digits on any sales¹.

The terms

The candidates are antibody-drug conjugates (ADCs) and T cell engagers (TCEs), and every one is still preclinical¹. Five come from LaNova Medicines, which SBP Group bought in 2025 for around $500 million and now owns outright. The sixth comes from Beijing Tide Pharmaceutical, another SBP Group subsidiary¹.

The deal splits the work by stage. SBP Group runs the early development of each candidate, and Boehringer takes over once agreed clinical milestones are met¹. That structure leaves the cost and risk of the first steps with the Chinese partner and gives Boehringer the choice of which assets to carry into global trials¹.

The new agreement reverses the direction of the companies' first alliance. In 2024 it was SBP Group that took rights to three of Boehringer's cancer candidates for the Chinese market: the HER2 inhibitor zongertinib, the MDM2-p53 antagonist brigimadlin and the DLL3/CD3-directed BI 764532¹.

Paola Casarosa, head of Boehringer's innovation unit, said the partnership "puts our China strategy into action by connecting innovation from China with our global research and development capabilities"¹.

What it means for the market

The size stands out against Boehringer's record. Its licensing deals have usually carried ceilings of about $1 billion to $2 billion, which places this agreement among the largest the company has signed¹. The privately held German group has built a steady line of Chinese deals: a $1.25 billion agreement with Simcere Pharma earlier this year for an early-stage inflammatory bowel disease candidate, and a $2 billion siRNA partnership with Suzhou Ribo Life Science in 2024 covering liver and cardiometabolic disease¹. It has also run an external innovation hub in Shanghai since 2020¹.

For investors and business development teams, the deal adds weight to China as a source of early oncology assets. China now accounts for around a third of pharma industry pipeline projects worldwide¹. Option structures with modest upfront payments and large back-ended milestones let a buyer secure several shots at once while paying in full only for programmes that reach the clinic.

For SBP Group, the agreement puts a price on the LaNova purchase. The $358 million upfront payment alone is larger than what SBP Group paid for the subsidiary in 2025¹, although most of the headline value depends on milestones that may never be reached.

Caveats

All six candidates are preclinical, so none has yet been tested in people¹. The $7 billion figure is a ceiling made up of milestones and depends on the candidates advancing¹. The report does not break down how the milestones are divided between development, regulatory and sales events, or which of the six assets Boehringer expects to take forward. Boehringer will assume development only after the agreed clinical milestones are reached¹.